Get the Stockscreener App
14.75
4.84%
-0.75
After Hours:
15.05
0.30
+2.03%
Maze Therapeutics Inc stock is traded at $14.75, with a volume of 270.01K.
It is down -4.84% in the last 24 hours and up +20.21% over the past month.
Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.
See More
Previous Close:
$15.50
Open:
$15.13
24h Volume:
270.01K
Relative Volume:
2.06
Market Cap:
$646.01M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-10.33%
1M Performance:
+20.21%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$14.20
$15.68
1-Week Range:
$14.20
$17.38
52-Week Range:
$6.71
$18.67
Maze Therapeutics Inc Stock (MAZE) Company Profile
Name
Maze Therapeutics Inc
Sector
Industry
Phone
(650) 850-5070
Address
171 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO
Compare MAZE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MAZE
Maze Therapeutics Inc
|
14.75 | 678.86M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.87 | 120.48B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.46 | 59.88B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
392.24 | 44.31B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
670.33 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
301.13 | 32.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Maze Therapeutics Inc Stock (MAZE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-23-25 | Initiated | H.C. Wainwright | Buy |
| Jul-08-25 | Initiated | Wedbush | Outperform |
Maze Therapeutics Inc Stock (MAZE) Latest News
How to build a custom watchlist for Maze Therapeutics Inc.ROI Focused Setup Screener With Exit Markers - Newser
What makes Maze Therapeutics Inc. stock price move sharplyDaily Trading Opportunities For Fast Growth - jammulinksnews.com
A Note On Maze Therapeutics, Inc.'s (NASDAQ:MAZE) ROE and Debt To Equity - simplywall.st
Maze Therapeutics, Inc. (NASDAQ:MAZE) Has A ROE Of 18% - Yahoo Finance
Buy Signal for Maze Therapeutics Inc. Stock Key Technical Indicators to WatchSmart Risk Entry Zone Technical Analysis - Newser
How to escape a deep drawdown in Maze Therapeutics Inc.Buy Opportunity Forecast for Fast Traders - Newser
Why Maze Therapeutics Inc. stock attracts strong analyst attentionLong-Term Safety Investment Analysis Report - Newser
How Maze Therapeutics Inc. stock performs during market volatilityAI-Powered Stock Trend Movement Analysis - Newser
What is Maze Therapeutics Inc. company’s growth strategyEntry Signal Alerts With Low Risk - jammulinksnews.com
Maze Therapeutics Inc. Added to Custom Quant Screener TodayGrowth Based Stock Signal Screener Updated - metal.it
Institutional scanner results for Maze Therapeutics Inc.Free Multi-Bagger Potential Stock Forecast Tools - Newser
Visual trend scoring systems applied to Maze Therapeutics Inc.Free Price Action Based Buy Opportunity List - Newser
Is Maze Therapeutics Inc. stock poised for growthHigh Return Strategy with Low Risk - Newser
How does Maze Therapeutics Inc. generate profit in a changing economyRetirement Planning Growth Plan With Proven Results - jammulinksnews.com
Can Maze Therapeutics Inc. Overcome Bearish SentimentMulti-Bagger Potential Stock Forecast Tools Released - metal.it
Is Maze Therapeutics Inc. a growth stock or a value stockUnlock exclusive trading strategies for gains - jammulinksnews.com
What to do if you’re stuck in Maze Therapeutics Inc. Next Day Momentum Stock Forecasting Report - Newser
Is Maze Therapeutics Inc. stock overvalued or undervaluedStay ahead with daily market updates - jammulinksnews.com
When is Maze Therapeutics Inc. stock expected to show significant growthFree Stock Chart Pattern Guide - jammulinksnews.com
What is the dividend policy of Maze Therapeutics Inc. stockExplosive portfolio gains - jammulinksnews.com
How volatile is Maze Therapeutics Inc. stock compared to the marketExplosive capital appreciation - jammulinksnews.com
Is Maze Therapeutics Inc. Stock a Smart Buy in 2025 Investment Analysis Inside10x Return With Managed Risk - Newser
Q2 Earnings Estimate for MAZE Issued By HC Wainwright - Defense World
HC Wainwright Initiates Coverage on Maze Therapeutics (NASDAQ:MAZE) - MarketBeat
What analysts say about Maze Therapeutics Inc. stockExceptional profit potential - PrintWeekIndia
What institutions are buying Maze Therapeutics Inc. stock nowFree Trading Strategy Suggestions - jammulinksnews.com
Is Maze Therapeutics Inc. a good long term investmentFree Stock Market Knowledge Sharing - PrintWeekIndia
What drives Maze Therapeutics Inc. stock priceExtraordinary performance - Autocar Professional
Maze Therapeutics Inc. Stock Analysis and ForecastTremendous wealth creation - Autocar Professional
This Celsius Holdings Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
H.C. Wainwright initiates coverage on Maze Therapeutics stock with Buy rating - Investing.com UK
Maze Therapeutics, Inc.: Buy Rating Initiated on Precision Nephrology Potential and Undervalued Stock - TipRanks
Maze Therapeutics, Inc.’s (NASDAQ:MAZE) Lock-Up Period To Expire on July 30th - Defense World
Maze Therapeutics Inc Stock (MAZE) Financials Data
There is no financial data for Maze Therapeutics Inc (MAZE). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
3.43%
2.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):